More than a quarter million people screened for risk

For 10-year-old Brynlee Clevenger, it was the possibility of helping other kids with type 1 diabetes (T1D) that prompted her to join a clinical trial.

Pathway to Prevention Study Chair Laura Jacobsen, MD, is an assistant professor and pediatric endocrinologist at the University of Florida, Gainesville.

With four boys who are active in multiple sports, the Ebners are a busy family. But when one of the Ebner sons was diagnosed with type 1 diabetes (T1D), the family made the time for T1D research.

World-first study findings by Australian researchers show a daily pill containing the JAK inhibitor baricitinib can preserve insulin production in people newly diagnosed with T1D. Published in the December issue of the New England Journal of Medicine, findings were co-authored by Thomas Kay, MBBS, PhD,  and Helen Thomas, PhD, St.

TrialNet Chair Kevan C. Herold, MD, Yale University, reflects on key accomplishments of the past year and shares direction for 2024 and beyond.

Dear TrialNet family,

As we start the new year, I want to take time to recognize TrialNet’s major achievements in 2023 and share our direction for advancing type 1 diabetes (T1D) research in the year ahead.

Photo courtesy of JDRF Southern & Central Ohio Chapter

During what proved to be an unforgettable celebration by the JDRF community in Cincinnati, NFL Super Bowl Champion and Bengals offensive lineman Orlando Brown, Jr. encouraged relatives of people with type 1 diabetes (T1D) to get screened by TrialNet to help advance research.

Amber Van Den Heuvel received low-dose anti-thymocyte globulin (ATG) in 2015 as a participant in a TrialNet clinical study for people newly diagnosed with type 1 diabetes (T1D). Five years later, she still had beta cell function. Today, at age 26, Amber is encouraging people at high risk for T1D to consider participating in a TrialNet prevention study using the same therapy.

TrialNet’s latest clinical study will test two established immune therapies—rituximab-pvvr followed by abatacept—to see if the combination can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).

TrialNet researchers are testing two promising new treatments to see if either or both can preserve insulin production in people recently diagnosed with type 1 diabetes (T1D).